News & Updates

A phase III study presented at EADV 2023 demonstrated the similarity between SB17, a human monoclonal antibody and proposed ustekinumab biosimilar, and reference ustekinumab for the treatment of moderate-to-severe plaque psoriasis.

Nearly half of individuals with a newly diagnosed type 1 (T1D) or type 2 diabetes (T2D) suffer from gastrointestinal (GI) symptoms, according to a study presented at EASD 2023. These GI adverse events that are associated with glucose-lowering medications occur more frequently among those with already existing GI symptoms prior to treatment initiation.

Early antihypertensive treatment appears to have no significant benefits in terms of dependency or death at 90 days among patients with mild-to-moderate acute ischaemic stroke and systolic blood pressure (SBP) between 140 and <220 mm Hg, reports a study.

In the phase III ARCADIA 1 and 2 trials, the investigational, first-in-class interleukin-31-Rα antagonist nemolizumab delivered early, rapid, and sustained improvements in the core signs and symptoms of atopic dermatitis (AD) in patients with moderate-to-severe disease.

Dapagliflozin reduced HbA_1c by 1.03 percentage points more than placebo in children and adolescents with type 2 diabetes (T2D), while saxagliptin showed no significant reduction vs placebo in the phase III T2NOW trial presented at EASD 2023.

Clinical trials on first-line therapies for advanced or metastatic nonsmall cell lung cancer (NSCLC) from 2010 to 2020 have reported better survival and a steady improvement in quality of life (QoL) among patients, according to the results of a systematic review.